Cargando…
Correction to: “Cardiovascular Benefits of Empagliflozin Are Associated With Gut Microbiota and Plasma Metabolites in Type 2 Diabetes”
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681615/ https://www.ncbi.nlm.nih.gov/pubmed/36104307 http://dx.doi.org/10.1210/clinem/dgac506 |
| _version_ | 1784834654678810624 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9681615 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96816152022-11-25 Correction to: “Cardiovascular Benefits of Empagliflozin Are Associated With Gut Microbiota and Plasma Metabolites in Type 2 Diabetes” J Clin Endocrinol Metab Correction Oxford University Press 2022-09-14 /pmc/articles/PMC9681615/ /pubmed/36104307 http://dx.doi.org/10.1210/clinem/dgac506 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
| spellingShingle | Correction Correction to: “Cardiovascular Benefits of Empagliflozin Are Associated With Gut Microbiota and Plasma Metabolites in Type 2 Diabetes” |
| title | Correction to: “Cardiovascular Benefits of Empagliflozin Are Associated With Gut Microbiota and Plasma Metabolites in Type 2 Diabetes” |
| title_full | Correction to: “Cardiovascular Benefits of Empagliflozin Are Associated With Gut Microbiota and Plasma Metabolites in Type 2 Diabetes” |
| title_fullStr | Correction to: “Cardiovascular Benefits of Empagliflozin Are Associated With Gut Microbiota and Plasma Metabolites in Type 2 Diabetes” |
| title_full_unstemmed | Correction to: “Cardiovascular Benefits of Empagliflozin Are Associated With Gut Microbiota and Plasma Metabolites in Type 2 Diabetes” |
| title_short | Correction to: “Cardiovascular Benefits of Empagliflozin Are Associated With Gut Microbiota and Plasma Metabolites in Type 2 Diabetes” |
| title_sort | correction to: “cardiovascular benefits of empagliflozin are associated with gut microbiota and plasma metabolites in type 2 diabetes” |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681615/ https://www.ncbi.nlm.nih.gov/pubmed/36104307 http://dx.doi.org/10.1210/clinem/dgac506 |